Skip to main content

Table 1 Chromosomal translocation and fusion proteins in solid tumors involving ALK gene

From: Novel ALK inhibitors in clinical use and development

Disease

Chromosomal rearrangement

Fusion protein

Frequency (%)

Reference

NSCLC

inv(2)(p21;p23)

EML4-ALK

2-5

[59,64,65]

 

t(2;3)(p23;q21)

TFG-ALK

2

[65]

 

t(2;10)(p23;p11)

KIF5B-ALK

<1

[53,57]

 

t(2;14)(p23;q32)

KLC1-ALK

<5

[55]

 

t(2;9)(p23;q31)

PTPN3-ALK

ND

[50]

IMT

t(1;2)(q25;p23)

TPM3-ALK

0.5

[24]

 

t(2;19)(p23;p13)

TPM4-ALK

<5

[24]

 

t(2;17)(p23;q23)

CLTC-ALK

<5

[40,42,43]

 

inv(2)(p23;q35)

ALK-ATIC

<5

[32]

 

t(2;11;2)(p23;p15;q31)

CARS-ALK

<5

[34,35]

 

t(2;2)(p23;q13)

RANBP2-ALK

<5

[36]

 

inv(2)(p23;p15;q31)

RANBP2-ALK

<5

[38]

 

t(2;4)(p23;q21)

SEC31L1-ALK

<5

[52]

BC

inv(2)(p21;p23)

EML4-ALK

<5

[64]

CRC

inv(2)(p21;p23)

EML4-ALK

<5

[64]

 

t(2;2)(p23.3)

C2orf44-ALK

<5

[51]

ESCC

t(2;19)(p23;p13)

TPM4-ALK

ND

[27,28]

RCC

t(2;10)(p23;q22)

VCL-ALK

ND

[47]

 

t(1;2)(q25;p23)

TPM3–ALK

ND

[23]

 

inv(2)(p21;p23)

EML4–ALK

ND

[23]

  1. NSCLC; non small cell lung cancer, IMT; inflammatory myofibroblastic tumor, BC; breast cancer, CRC; colorectal cancer, ESCC; esophageal squamous cell carcinoma, RCC; renal cell carcinoma, ND; not determined.